CommercialJuly 1, 2021
Certain specialty medication precertification requests may require additional documentation
Upon request, providers shall submit documentation from the member’s medical record for each policy question flagged for documentation. A denial may result if documentation does not support medical necessity.
Should you have any questions, please refer to our Clinical Criteria policy webpage for specific medication criteria details, including documentation requirements.
Impacted Policy |
Impacted Medication(s) |
ING-CC-0153: Adakveo (crizanlizumab) |
Adakveo |
ING-CC-0065: Agents for Hemophiilia A and von Willebrand Disease |
Advate, Adynovate, Afstyla, Alphanate, Eloctate, Esperoct, Helixate FS, Hemlibra, Hemofil-M, Humate-P, Jivi, Koate-DVI, Kogenate FS, Kovaltry, Monoclate-P, Novoeight, Nuwiq, Obizur, Recombinate, Wilate, Xyntha |
ING-CC-0148: Agents for Hemophilia B |
Alphanine SD, Alprolix, Bebulin, Benefix, Idelvion, Ixinity, Mononine, Profilnine SD, Rebinyn, Rixubis |
ING-CC-0025: Aldurazyme (laronidase) |
Aldurazyme |
ING-CC-0073: Alpha-1 Proteinase Inhibitor Therapy |
Aralast, Glassia, Prolastin-C, Zemaira |
ING-CC-0028: Benlysta (belimumab) |
Benlysta |
ING-CC-0012: Brineura (cerliponase alfa) |
Brineura |
ING-CC-0137: Cablivi (caplacizumab-yhdp) |
Cablivi |
ING-CC-0041: Complement Inhibitors |
Soliris, Ultomiris |
ING-CC-0081: Crysvita (burosumab-twza) |
Crysvita |
ING-CC-0035: Duopa (carbidopa and levodopa enteral suspension) |
Duopa |
ING-CC-0029: Dupixent (dupilumab) |
Dupixent |
ING-CC-0069: Egrifta (tesamorelin) |
Egrifta |
ING-CC-0024: Elaprase (idursufase) |
Elaprase |
ING-CC-0173: Enspryng (satralizumab-mwge) |
Enspryng |
ING-CC-0051: Enzyme Replacement Therapy for Gaucher Disease |
Cerezyme, Elelyso, Vpriv |
ING-CC-0044: Exondys 51 (eteplirsen) |
Exondys 51 |
ING-CC-0021: Fabrazyme (agalsidase beta) |
Fabrazyme |
ING-CC-0068: Growth hormone |
Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive |
ING-CC-0034: Hereditary Angioedema Agents |
Berinert, Cinryze, Firazyr, Haegarda, Kalbitor, Ruconest, Takhzyro |
ING-CC-0188: Imcivree (setmelanotide) |
Imcivree |
ING-CC-0070: Jetrea (ocriplasmin) |
Jetrea |
ING-CC-0037: Kanuma (sebelipase alfa) |
Kanuma |
ING-CC-0057: Krystexxa (pegloticase) |
Krystexxa |
ING-CC-0018: Lumizyme (alglucosidase alfa) |
Lumizyme |
ING-CC-0013: Mepsevii (vestronidase alfa) |
Mepsevii |
ING-CC-0043: Monoclonal Antibodies to Interleukin-5 |
Cinqair, Fasenra, Nucala |
ING-CC-0023: Naglazyme (galsulfase) |
Naglazyme |
ING-CC-0111: Nplate (romiplostim) |
Nplate |
ING-CC-0082: Onpattro (patisiran) |
Onpattro |
ING-CC-0077: Palynziq (pegvaliase-pqpz) |
Palynziq |
ING-CC-0049: Radicava (edaravone) |
Radicava |
ING-CC-0156: Reblozyl (luspatercept) |
Reblozyl |
ING-CC-0159: Scenesse (afamelanotide) |
Scenesse |
ING-CC-0149: Select Clotting Agents for Bleeding Disorders |
Feiba, Novoseven |
ING-CC-0079: Strensiq (asfotase alfa) |
Strensiq |
ING-CC-0008: Subcutaneous Hormonal Implants |
Testopel |
ING-CC-0084: Tegsedi (inotersen) |
Tegsedi |
ING-CC-0162: Tepezza (teprotumumab-trbw) |
Tepezza |
ING-CC-0170: Uplizna (inebilizumab) |
Uplizna |
ING-CC-0172: Viltepso (viltolarsen) |
Viltepso |
ING-CC-0022: Vimizim (elosulfase alfa) |
Vimizim |
ING-CC-0152: Vyondys 53 (golodirsen) |
Vyondys 53 |
ING-CC-0017: Xiaflex (clostridial collagenase histolyticum) injection |
Xiaflex |
ING-CC-0033: Xolair (omalizumab) |
Xolair |
PUBLICATIONS: July 2021 Anthem Provider News - Georgia
To view this article online:
Or scan this QR code with your phone